Targeted signal transduction therapies in myeloid malignancies

Current Oncology Reports

Volumn 12, Issue 6, 2010, Pages 358-365

  Scott, Emma ^a   Hexner, Elizabeth ^a   Perl, Alexander ^a   Carroll, Martin ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acute myeloid leukemia; BCR ABL; Chronic myeloid leukemia; Imatinib; JAK2; Myeloproliferative neoplasms; Nilotinib; Signal transduction

Indexed keywords

ABELSON KINASE INHIBITOR; AMINOTRANSFERASE; ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BOSUTINIB; CD135 ANTIGEN INHIBITOR; CYTARABINE; DASATINIB; DAUNORUBICIN; FLT3 LIGAND; IDARUBICIN; IMATINIB; INCB 01824; INTERFERON; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; KW 2449; LESTAURTINIB; MIDOSTAURIN; NILOTINIB; PHENYLALANINE; PKC 412A; PLX 4032; PROTEIN TYROSINE KINASE; SORAFENIB; SUNITINIB; TANDUTINIB; TG 101348; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; ANEMIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOGENETICS; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDEMA; ENZYME ACTIVITY; EVENT FREE SURVIVAL; FLUID RETENTION; GASTROINTESTINAL TOXICITY; GENE MUTATION; HUMAN; LEUKEMIA REMISSION; MELANOMA; MONOTHERAPY; MUSCLE CRAMP; MUSCLE SPASM; MYELOPROLIFERATIVE DISORDER; MYOSITIS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PLEURA EFFUSION; PRURITUS; QT PROLONGATION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG RESISTANCE, NEOPLASM; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIGNAL TRANSDUCTION;

EID: 78649907384     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-010-0126-z     Document Type: Review

References (50)

1. UNAIDS: WHO Classification of Tumors of the Haemopoietic and Lymphoid Tissues. Edited by Swerdlow CE, Harris SH. WHO; 2008.
2. BJ Druker, et al. 2006 Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2408 2417 1:CAS:528: DC%2BD28Xht12ntrzM 10.1056/NEJMoa062867 17151364 (Pubitemid 44903745)
3. A Hochhaus, et al. 2008 Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib Leukemia 22 1200 1206 1:CAS:528:DC%2BD1cXntVCjurw%3D 10.1038/leu.2008.84 18401416 (Pubitemid 351833788)
4. HM Kantarjian, et al. 2007 Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance Blood 110 3540 3546 1:CAS:528:DC%2BD2sXhtlarur3P 10.1182/blood-2007-03-080689 17715389 (Pubitemid 350159618)
5. E Weisberg, et al. 2005 Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 7 129 141 1:CAS:528: DC%2BD2MXitFygu7o%3D 10.1016/j.ccr.2005.01.007 15710326 (Pubitemid 40248339)
6. NP Shah, et al. 2004 Overriding imatinib resistance with a novel ABL kinase inhibitor Science 305 399 401 1:CAS:528:DC%2BD2cXls1egtrY%3D 10.1126/science.1099480 15256671 (Pubitemid 38938156)
7. HM Kantarjian, et al. 2010 Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase Cancer 116 1419 1430 1:CAS:528: DC%2BC3cXktFGgsL4%3D 10.1002/cncr.24928 20120030
8. •• Saglio G, et al.: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362(24):2251-2259.
9. •• Kantarjian H, et al.: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362(24):2260-2270.
10. W Dameshek 1951 Some speculations on the myeloproliferative syndromes Blood 6 372 375 1:STN:280:DyaG3M%2FltVGnsw%3D%3D 14820991
11. EJ Baxter, et al. 2005 Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet 365 1054 1061 1:CAS:528: DC%2BD2MXisFGrs7g%3D 15781101
12. R Kralovics, et al. 2005 A gain-of-function mutation of JAK2 in myeloproliferative disorders N Engl J Med 352 1779 1790 1:CAS:528: DC%2BD2MXjsFyhsLw%3D 10.1056/NEJMoa051113 15858187 (Pubitemid 40570926)
13. RL Levine, et al. 2005 Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Cancer Cell 7 387 397 1:CAS:528:DC%2BD2MXjvFSku7o%3D 10.1016/j.ccr.2005.03.023 15837627 (Pubitemid 40544655)
14. C James, et al. 2005 A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 434 1144 1148 1:CAS:528:DC%2BD2MXjsF2ltbk%3D 10.1038/nature03546 15793561 (Pubitemid 40663494)
15. EO Hexner, et al. 2008 Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders Blood 111 5663 5671 1:CAS:528:DC%2BD1cXnsVOktbw%3D 10.1182/blood-2007-04-083402 17984313
16. A Pardanani, et al. 2007 TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations Leukemia 21 1658 1668 1:CAS:528:DC%2BD2sXnvVeltLo%3D 10.1038/sj.leu.2404750 17541402 (Pubitemid 47086756)
17. A Quintas-Cardama, et al. 2010 Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms Blood 115 3109 3117 1:CAS:528:DC%2BC3cXltlWqsr8%3D 10.1182/blood-2009-04-214957 20130243
18. Verstovsek S, Kantarjian H, Mesa RA, et al.: Long-term follow up and optimized dosing regimen of INCB018424 in patients with myelofibrosis: durable clinical, functional and symptomatic responses with improved hematological safety. In 51st American Society of Hematology. New Orleans: 2009.
19. Pardanani A, Gotlib JR, Jamieson C, et al.: A phase I evaluation of TG101348, a selective JAK2 inhibitor, in myelofibrosis: clinical response is accompanied by significant reduction in JAK2V617F allele burden. In 51st American Society of Hematology. New Orleans: 2009.
20. FP Santos, et al. 2010 Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis Blood 115 1131 1136 1:CAS:528:DC%2BC3cXisFyrt7k%3D 10.1182/blood-2009-10-246363 20008298
21. Hexner E, Goldberg JD, Prchal JT, et al.: A multicenter, open label phase I/II study of CEP701 (lestaurtinib) in adults with myelofibrosis; a report on phase I: A Study of the Myeloproliferative Disorders Research Consortium (MPD-RC). In 51st American Society of Hematology. New Orleans: 2009.
22. RA Mesa, et al. 2009 The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis Leuk Res 33 1199 1203 10.1016/j.leukres.2009.01.035 19250674
23. Moliterno A, Hexner E, Roboz GJ, et al.: An open-label study of CEP-701 in patients with JAK2 V617F-positive PV and ET: update of 39 enrolled patients. In 51st American Society of Hematology. New Orleans: 2009.
24. Verstovsek S, Passamonti F, Rambaldi A, et al.: A Phase 2 study of INCB018424, an oral, selective JAK1/JAK2 inhibitor, in patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET) refractory to hydroxyurea. In 51st American Society of Hematology. New Orleans: 2009.
25. Swerdlow SH, Harris CN: WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008.
26. AH Goldstone, et al. 2001 Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial Blood 98 1302 1311 1:CAS:528: DC%2BD3MXmvFGjtr8%3D 10.1182/blood.V98.5.1302 11520775
27. JM Rowe, et al. 2004 A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group Blood 103 479 485 1:CAS:528: DC%2BD2cXmsFCjsw%3D%3D 10.1182/blood-2003-05-1686 14512295 (Pubitemid 38140076)
28. ER Mardis, et al. 2009 Recurring mutations found by sequencing an acute myeloid leukemia genome N Engl J Med 361 1058 1066 1:CAS:528:DC%2BD1MXhtFaltLvL 10.1056/NEJMoa0903840 19657110
29. FG Rucker, et al. 2006 Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization J Clin Oncol 24 3887 3894 10.1200/JCO.2005.04.5450 16864856 (Pubitemid 46630736)
30. RF Schlenk, et al. 2008 Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia N Engl J Med 358 1909 1918 1:CAS:528:DC%2BD1cXlt1Ggu70%3D 10.1056/NEJMoa074306 18450602 (Pubitemid 351620111)
31. J Suela, et al. 2007 DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups Leukemia 21 1224 1231 1:CAS:528: DC%2BD2sXlsFOhsro%3D 10.1038/sj.leu.2404653 17377590 (Pubitemid 46831812)
32. D Small, et al. 1994 STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells Proc Natl Acad Sci USA 91 459 463 1:CAS:528:DyaK2cXktVaitrY%3D 10.1073/pnas.91.2.459 7507245
33. Small D: FLT3 mutations: biology and treatment. Hematol Am Soc Hematol Educ Program 2006, 178-184.
34. Y Yamamoto, et al. 2001 Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies Blood 97 2434 2439 1:CAS:528:DC%2BD3MXivFOgtbk%3D 10.1182/blood.V97.8.2434 11290608 (Pubitemid 32291491)
35. J Griffith, et al. 2004 The structural basis for autoinhibition of FLT3 by the juxtamembrane domain Mol Cell 13 169 178 1:CAS:528:DC%2BD2cXhsFOiu7g%3D 10.1016/S1097-2765(03)00505-7 14759363 (Pubitemid 38183264)
36. M Levis D Small 2003 FLT3: It does matter in leukemia Leukemia 17 1738 1752 1:CAS:528:DC%2BD3sXntFChsro%3D 10.1038/sj.leu.2403099 12970773 (Pubitemid 37185249)
37. H Kiyoi, et al. 2002 Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain Oncogene 21 2555 2563 1:CAS:528:DC%2BD38Xjtlemur0%3D 10.1038/sj.onc.1205332 11971190
38. FM Abu-Duhier, et al. 2001 Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia Br J Haematol 113 983 988 1:CAS:528: DC%2BD3MXlslalsbg%3D 10.1046/j.1365-2141.2001.02850.x 11442493 (Pubitemid 32634768)
39. PD Kottaridis, et al. 2001 The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials Blood 98 1752 1759 1:CAS:528: DC%2BD3MXntFWgsbg%3D 10.1182/blood.V98.6.1752 11535508
40. K Pratz M Levis 2008 Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens Leuk Lymphoma 49 852 863 1:CAS:528: DC%2BD1cXnsFaqsrk%3D 10.1080/10428190801895352 18452067 (Pubitemid 351942737)
41. RM Stone, et al. 2005 Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 Blood 105 54 60 1:CAS:528:DC%2BD2MXis1GksA%3D%3D 10.1182/blood-2004-03-0891 15345597 (Pubitemid 40053063)
42. BD Smith, et al. 2004 Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia Blood 103 3669 3676 1:CAS:528:DC%2BD2cXjvF2itb4%3D 10.1182/blood-2003-11-3775 14726387 (Pubitemid 38596280)
43. FJ Giles, et al. 2003 SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes Blood 102 795 801 1:CAS:528: DC%2BD3sXlvFCms7c%3D 10.1182/blood-2002-10-3023 12649163 (Pubitemid 36917765)
44. AM O'Farrell, et al. 2003 An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients Clin Cancer Res 9 5465 5476 14654525
45. • Ravandi F, et al.: Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010, 28(11):1856-1862.
46. KW Pratz, et al. 2009 A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response Blood 113 3938 3946 1:CAS:528:DC%2BD1MXlsVWrsLg%3D 10.1182/blood-2008-09-177030 19029442
47. Cortes JFJ, Ghirdaladze D, et al.: AC220, a potent, selective, second generation FLT3 receptor tyrosine kinase (RTK) inhibitor, in a first-in-human (FIH) phase 1 AML study. In 51st Meeting of the American Society of Hematology. New Orleans: 2009.
48. Levis M, Wang RF, et al.: Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for FLT3 mutant AML patients in first relapse. In 51st Meeting of the American Society of Hematology. New Orleans: 2009.
49. PP Zarrinkar, et al. 2009 AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) Blood 114 2984 2992 1:CAS:528:DC%2BD1MXht12qurzN 10.1182/blood-2009-05-222034 19654408
50. Stone RM, et al.: A phase 1b study of midostaurin (PKC412) in combination with daunorubicin and cytarabine induction and high-dose cytarabine consolidation in patients under age 61 with newly diagnosed de novo acute myeloid leukemia: Overall survival of patients whose blasts have FLT3 mutations is similar to those with wild-type FLT3. In 51st Meeting of the American Society of Hematology. New Orleans: 2009.